Subscribe to
this category
r

Pricing

A total of 12 posts are filed under Pricing
ICER Says Roche’s Hemophilia A Therapy Improves Health While Lowering Costs
Rare Daily Staff The Institute for Clinical and Economic Review, an independent, nonprofit that analyzes the cost-effectiveness of… Continue Reading
NICE Draft Guidance Says BioMarin’s ERT for Batten Disease Not Cost Effective
Rare Daily Staff The United Kingdom’s National Institute for Health and Care Excellence issued a preliminary recommendation not to… Continue Reading
ICER Analysis Finds Spark Gene Therapy Priced Too High
Rare Daily Staff The Institute for Clinical and Economic Review, an independent non-profit research institute that analyzes the evidence on… Continue Reading
Measuring the Value of Therapies for Ultra-Rare Diseases
  The pricing of drugs is characterized by a tension between providing incentives to drug companies to invest in the development of… Continue Reading
Duchenne UK Collaborates with Industry to Speed Payer Value Assessments
Rare Daily Staff Duchenne UK has launched a collaboration with five pharmaceutical companies developing treatments for Duchenne muscular… Continue Reading
ICER Issues Modified Framework for Assessing Value of Treatments for Ultra-Rare Diseases
Rare Daily Staff The Institute for Clinical and Economic Review, an independent non-profit research institute that analyzes the evidence on… Continue Reading
Paying for Value
The drug industry long justified the pricing of its products on the basis of the high cost of R&D and the need for successes to offset the… Continue Reading
be-a-guest-blogger

Follow us on Twitter